Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jennifer H, Black"'
Autor:
Daniel A. Vallera, Jennifer H Black, Peter D. Aplan, Ursula R. Kees, J. Ramage, Arthur E. Frankel
Publikováno v:
Leukemia Research. 27:79-84
Diphtheria fusion proteins are a novel class of agents for the treatment of chemotherapy resistant acute myelogenous leukemia (AML). We prepared diphtheria toxin/urokinase fusion protein (DTAT) composed of the amino terminal fragment of the urokinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bca9892c98acd6c561311bfee713764
https://doi.org/10.1016/s0145-2126(02)00077-2
https://doi.org/10.1016/s0145-2126(02)00077-2
Autor:
Jennifer H. Black, Asha Surendranathan, Kristen Ganjoo, Larry D. Cripe, Arthur E. Frankel, Angela White
Publikováno v:
Cancer. 106(10)
BACKGROUND The safety and efficacy of the interleukin-2 diphtheria toxin fusion protein (DAB389IL2; denileukin diftitox) directed against the IL-2 receptor (IL-2R) was tested in patients with recurrent or refractory chronic lymphocytic leukemia (CLL)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68d39c03a496feac6961c4fc0db12fcf
https://pubmed.ncbi.nlm.nih.gov/16586495
https://pubmed.ncbi.nlm.nih.gov/16586495
Autor:
Arthur E, Frankel, Donald R, Fleming, Philip D, Hall, Bayard L, Powell, Jennifer H, Black, Carole, Leftwich, Ronald, Gartenhaus
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(10 Pt 1)
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have a poor prognosis. We tested the safety and efficacy in these patients of a diphtheria fusion protein DAB(389)IL2 (denileukin diftitox) directed against the interleukin 2 rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::619b4c7a239939c187c986c01b078567
https://pubmed.ncbi.nlm.nih.gov/15161717
https://pubmed.ncbi.nlm.nih.gov/15161717
Autor:
Robert O. Kerr, Jesus G. Berdeja, Philip Kuriakose, Jennifer H Black, Asha Surendranathan, Francesco Turturro, Arthur E. Frankel
Publikováno v:
Blood. 104:4824-4824
Therapeutic options for chronic lymphocytic leukemia (CLL) at relapse are limited because of myelosuppressive toxicity. Denileukin diftitox (ONTAK®, Ligand Pharmaceuticals) is a genetically engineered fusion protein comprising the enzymatically acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbbb83040554ad4f93fc9c6e8eb7f5ff
https://doi.org/10.1182/blood.v104.11.4824.4824
https://doi.org/10.1182/blood.v104.11.4824.4824
Autor:
Patricia H. Davis, Carlos M. de Castro, Philip D. Hall, Cristina Gasparetto, Jennifer H Black, Nelson J. Chao, Jon P. Gockerman, Tie Fu Liu, Joseph O. Moore, David A. Rizzieri, Mitchell E. Horwitz, Debashish Misra, Arthur E. Frankel
Publikováno v:
Blood. 104:4513-4513
Background: Although complete remission rates for AML are near 70% with combination induction and consolidation chemotherapy, most patients will relapse and die from the disease or treatment complications. New agents with unique mechanisms are needed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf7c204c2260b5e6ad518e00ae6cf355
https://doi.org/10.1182/blood.v104.11.4513.4513
https://doi.org/10.1182/blood.v104.11.4513.4513
Autor:
Arthur E. Frankel, Asha Surendranathan, Jennifer H. Black, Angela White, Kristen Ganjoo, Larry D. Cripe
Publikováno v:
Cancer (0008543X); May2006, Vol. 106 Issue 10, p2158-2164, 7p